期刊文献+

化疗药物对心脏毒副作用的心电图表现与病理分析 被引量:1

Electrocardiographic manifestations and pathological analysis of chemotherapy drugs on cardiac toxicity
下载PDF
导出
摘要 目的探究化疗药物对心脏毒副作用的心电图表现与病理概况。方法选取湖州市中心医院2015年1月~2017年2月接受化疗治疗的40例妇科肿瘤患者作为观察组;选择同期采用分泌疗法治疗的40例妇科肿瘤患者作为对照组;分析化疗对患者产生心脏毒副作用的心电图表现,同时探究其病理情况。结果化疗药物对心脏毒副作用的心电图表现为:室上性心动过速、偶有束支传导阻滞、ST-T段的非特异性改变、QRS低电压、QT间期延长、室性期前收缩等情况。对照组无心电图异常表现。结论化疗药物虽然能够产生一定治疗效果,但是会导致患者心电图异常表现,因此临床应该注重对患者实施联合治疗措施,或者控制药物用量,或者给予早期毒副作用的干预和预防,减少毒副作用对患者产生的影响。 Objective To explore the toxicity of chemotherapy drugs on ECG cardiac manifestations and pathological situation.Methods40cases of gynecologic cancer patients treated by chemotherapy in Huzhou Central Hospital from January2015to February2017were selected as observation group,and40cases of gynecologic tumor patients treated with secretory therapy were selected as control group.The ECG manifestations of cardiac toxic side effects of chemotherapy were analyzed,and the pathological condition was also explored.Results The electrocardiogram of chemotherapy drugs on cardiac toxicity for supraventricular tachycardia,with bundle branch block,nonspecific ST-T segment changes,QRS low voltage,QT prolongation,ventricular contractions and so on.The control group had no ECG abnormalities.Conclusion Although chemotherapy can produce a certain therapeutic effect,but can lead to patients with abnormal ECG findings,the clinical should pay attention to the combined treatment measures for patients,or drug control dosage,or give early intervention and prevention of toxic and side effects,reduce the toxic side effects on patients.
作者 林波 程震锋 LIN Bo;CHENG Zhen-feng(Electrocardiogram Room, Huzhou Central Hospital, Huzhou 313000, China;Department of Cardidogy, Huzhou Central Hospital, Huzhou 313000, China)
出处 《中国生化药物杂志》 CAS 2017年第12期400-401,共2页 Chinese Journal of Biochemical Pharmaceutics
关键词 化疗药物 心脏毒副作用 心电图表现 病理 chemotherapy drugs cardiac toxic side effects ECG manifestations pathology
  • 相关文献

参考文献6

二级参考文献51

  • 1郭晓峰,李变红,张爱玲.静脉化疗观察表的设计与应用[J].护理学杂志,2006,21(13):34-35. 被引量:3
  • 2Jemal A, siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, 58(2):71-96.
  • 3Simon GR, Sharma S, CantorA, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J]. Chest, 2005,127(3):978- 983.
  • 4Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer[J]. Clin Cancer Res, 2002,8(7):2286-2291.
  • 5Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer [J]. Int J Cancer, 2007, 1219(4):895-900.
  • 6Rosell R, CoboM, IsLa D, et al. ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage Ⅳ non-small-cell lung cancer patients[J]. J Clin Oncol, 2005, 23(16 Suppl):7002.
  • 7Rosell R, Mendez P, Isla D, et al. Platinum resistance related to a functional NER pathway[J]. J Thorac Oncol, 2007, 2(12):1063-1066.
  • 8Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first- line gemcitabine plus docetaxel in non-small-cell lung cancer patients[J]. PLoS One, 2008, 3(11):e3695.
  • 9Shiraishi K, Kohno T, Tanai C, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemo-therapy in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(33):4945-4952.
  • 10卫生部.国际疾病分类ICD-10应用指导手册[M].北京:中国协和医科大学出版社,2001.

共引文献42

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部